Drug firm CiplaNSE 0.81 % on Saturday said it has acquired four brands from Wanbury LtdNSE -1.10 % to strengthen its presence in the women's health segment.
Drug firm CiplaNSE 0.81 % on Saturday said it has acquired four brands from Wanbury LtdNSE -1.10 % to strengthen its presence in the women's health segment.
Wanbury Pharma, one of the largest exporters of diabetes drug metformin, has come under the lens of the European Medicines Agency (EMA) after the Maharashtra Food and Drug Administration launched an investigation of illegal packaging of drugs.
Wanbury is under lens for illegally exporting the API to Mexico, Brazil and Pakistan. Wanbury had low production capacity to make them and outsourced it to Pharmaceutical Products of India.
The central drug regulator’s attempts of having joint inspection with state bodies still seems to be far from sight, suggest the developments over WanburyBSE -3.17 % exporting an active pharmaceutical ingredient sourced from a third-party facility.
For years, low-priced raw material from China helped build India's generic drug industry into a global powerhouse. Now, that advantage is turning out to be the biggest weakness - if not a full-scale threat - for the country's bulk drug manufacturers.